Consequently, differences between patients with LRP4 myasthenia described so far and our patient with both CMS and CLS could be due to the consequences of direct binding defects of agrin to the mutated β1 propeller domain of LRP4. This evidence concerns the gene LRP4 and Fatigable weakness.